The company produces tests based on the science of nucleosomics, which identifies and measures fragments of chromosomes, called nucleosomes, in the bloodstream that can indicate if cancer is present.
Its scientists have found that cancer-related proteins that latch onto chromosomes in living cancer cells can also be detected when bound to nucleosomes in the blood of cancer patients.
The new patent covers the methods for measuring these nucleosome-protein bonds, known as "adducts."
The nucleosomics platform will be protected under patent 9187780 – titled the “Method for Detecting Nucleosome Adducts” – for 17 years.
Dr Jake Micallef, chief scientific officer, said: “This is a core technology patent for VolitionRx that we believe has an enormous potential application for non-invasive blood testing in cancer.”
He added the patent and technology will particularly help to measure oestrogen and androgen receptor adducts, which should be “pivotal” in detecting breast and prostate cancer.
Micallef said: “The new patent is a further milestone in VolitionRx's progress to build up a world-wide portfolio of intellectual property to protect its nucleosomics technology.”
It is the second US patent related to detecting proteins bound to nucleosomes, following the award of its first patent in September.
The initial patent covers a test that, using a single drop of blood, can detect epigenetic changes that affect chromosome structure in cancer.
Cameron Reynolds, chief executive, added that he expects more patents to be granted in the US.
The cancer test developer is also gearing up for important test results from its 4,800 patient colo-rectal cancer (CRC) study due early next year.
Initial results from the study published in September were encouraging, with a 67% detection rate for adenomas and higher percentages for other early and late stage colo-rectal cancer incidences.
Shares eased 1.35% to US$3.65.